Novo Nordisk says semaglutide cut obesity rates in young children in trial

Novo Nordisk ​said on ‌Monday that in a ​late-stage trial, ​40.4% of children ⁠aged 6 ​to under ​12 treated with semaglutide, the ​active ingredient ​in its blockbuster ‌weight-loss ⁠drug Wegovy, were...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。